drugset / Trial / NCT04379336

BCG Vaccination for Healthcare Workers in COVID-19 Pandemic

NCT04379336

Phase 3 Completed 1000 enrolled TASK Applied Science
RandomizedParallel-groupQuadruple-blindPrevention

Summary

A novel betacoronavirus, SARS-CoV-2, is spreading rapidly throughout the world. A large epidemic in South Africa may overwhelm available hospital capacity and healthcare resources which would be worsened by absenteeism of healthcare workers and other frontline staff (HCW). Strategies to prevent morbidity and mortality of HCW are desperately needed to safeguard continuous patient care. Bacillus Calmette-Guérin (BCG) is a vaccine against tuberculosis (TB), with protective non-specific effects against other respiratory tract infections in in vitro and in vivo studies, with reported morbidity and mortality reductions as high as 70%. We hypothesize that a BCG vaccination may reduce the morbidity and mortality of healthcare workers during the COVID-19 outbreak in South Africa.

Timeline

Start
2020-05-04
Primary completion
2022-01-02
Completion
2022-01-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Tremelimumab Monoclonal antibody 0.075 mg Other
Subject Tremelimumab Monoclonal antibody 0.1 ml Other

Indications